Core Viewpoint - The article discusses the rising popularity and effectiveness of Semaglutide, a GLP-1 receptor agonist, in weight loss and diabetes management, highlighting its approval for obesity treatment and its significant social media presence [2][4][29]. Group 1: Drug Approval and Popularity - Semaglutide was approved for oral use in 2019 and for obesity treatment by the FDA in 2021, with further approval for treating adolescent obesity in January 2023 [2]. - The drug has gained immense popularity on social media platforms, with tags like semaglutide accumulating hundreds of millions of views on TikTok, endorsed by public figures like Elon Musk [2]. Group 2: Administration and Efficacy - Oral Semaglutide and injectable Semaglutide show no significant difference in efficacy when stored and administered properly, allowing patients to choose based on their preferences [4]. - In a study, participants using Semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to a 2.4% loss in the placebo group [10][20]. Group 3: Mechanism of Action - Semaglutide works by suppressing appetite through central nervous system activation, slowing gastric emptying, and stabilizing blood sugar levels, which collectively help in reducing food intake [18][19][29]. - The drug's mechanism includes enhancing satiety signals and improving endothelial function, which is beneficial for cardiovascular health [18]. Group 4: Dosage and Side Effects - The recommended starting dose of oral Semaglutide is 3 mg daily, which can be increased to 7 mg and then to 14 mg based on individual needs [15]. - Common side effects include gastrointestinal symptoms such as nausea and abdominal discomfort, which should be monitored [17].